CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10012525,100125252,2,F,20131028,20140228,20140314,20150128,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-20448981,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20150128,N,CN,US,IN,EFAVIRENZ,Abortion induced;Pregnancy,100125252,OT,,,100125252,1,20080331,,,,100125252,1,HIV infection
10070585,100705854,4,F,20140227,20150106,20140410,20150123,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-20595633,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,65.8,KG,20150123,N,CN,US,MW,EFAVIRENZ,Anaemia;Bacterial sepsis;Lymph node tuberculosis,100705854,HO,,,100705854,1,20140219,,,,100705854,2,HIV infection
10155701,101557014,4,F,20140103,20150116,20140506,20150121,EXP,,UG-GILEAD-2014-0101523,GILEAD,,41,YR,A,M,Y,73,KG,20150121,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia;Bacteraemia;Kaposi's sarcoma,101557014,OT,,,101557014,1,20130724,20140423,,,101557014,1,HIV infection
10181438,101814383,3,F,,20150205,20140519,20150217,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-20734364,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150217,N,CN,US,GB,EFAVIRENZ,Neurotoxicity,101814383,OT,,,,,,,,,101814383,1,HIV infection
10184594,101845946,6,F,20140125,20150311,20140521,20150313,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-20777256,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20150313,N,CN,CI,CI,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,101845946,DE,,,101845946,1,20120612,,,,101845946,1,Antiretroviral therapy
10190829,101908292,2,F,,20150309,20140523,20150313,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20810222,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.3,KG,20150313,N,OT,ZA,ZA,EFAVIRENZ,Drug withdrawal syndrome neonatal;Endotracheal intubation;Exposure during breast feeding;Foetal exposure during pregnancy;Generalised tonic-clonic seizure,101908292,OT,,,,,,,,,101908292,1,Product used for unknown indication
10190830,101908302,2,F,,20150309,20140523,20150313,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20782470,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,2,KG,20150313,N,OT,ZA,ZA,EFAVIRENZ,Drug withdrawal syndrome neonatal;Exposure during breast feeding;Foetal exposure during pregnancy,101908302,HO,,,,,,,,,101908302,1,Product used for unknown indication
10250545,102505452,2,F,,20150109,20140620,20150126,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-20979142,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,,,20150126,N,CN,US,PT,EFAVIRENZ,Gastrointestinal disorder;Neurotoxicity;Skin disorder,102505452,OT,,,102505452,1,2007,,,,102505452,1,HIV infection
10262930,102629304,4,F,,20150107,20140626,20150114,EXP,,US-ELI_LILLY_AND_COMPANY-US201406008849,ELI LILLY AND CO,,,,,,Y,,,20150114,N,MD,US,US,SUSTIVA,Cleft lip;Congenital hand malformation;Foetal exposure during pregnancy,102629304,CA,,,,,,,,,102629304,1,Depression
10295788,102957885,5,F,,20150216,20140710,20150227,EXP,,US-GILEAD-2014-0107713,GILEAD,,,,N,F,Y,2.38,KG,20150227,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Unevaluable event,102957885,CA,,,102957885,1,20131005,20140623,,,102957885,1,HIV infection
10331651,103316515,5,F,20140516,20150128,20140722,20150205,EXP,,MW-ABBVIE-14P-100-1260062-00,ABBVIE,,0,DY,,M,Y,1.7,KG,20150205,N,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Acrochordon;Exposure during breast feeding;Foetal exposure during pregnancy;Premature baby,103316515,CA,,,,,,,,,103316515,1,Maternal exposure timing unspecified
10337771,103377712,2,F,20131014,20150311,20140724,20150313,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-21075809,BRISTOL MYERS SQUIBB,,,,I,F,Y,,,20150313,N,CN,US,CI,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,103377712,OT,,,,,,,,,103377712,1,Antiretroviral therapy
10393807,103938074,4,F,20140721,20150108,20140819,20150113,EXP,,BW-ABBVIE-14P-019-1272750-00,ABBVIE,,,,N,M,Y,,,20150113,N,MD,COUNTRY NOT SPECIFIED,BW,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby,103938074,HO,,,,,,,,,103938074,1,Maternal exposure timing unspecified
10412510,104125102,2,F,,20140819,20140827,20140827,EXP,,CM-SA-2014SA113509,AVENTIS,"WANDA F, NKEMENANG P, EHOUNOU G, TCHATON M, COMTE E, TRELLU LT, ET AL. CLINICAL FEATURES AND MANAGEMENT OF A SEVERE PARADOXICAL REACTION ASSOCIATED WITH COMBINED TREATMENT OF BURULI ULCER AND HIV CO-INFECTION. BMC INFECTIOUS DISEASE. 2014;14:423. AVAILABLE FROM: HTTP://WWW.BIOMEDCENTRAL.COM/1471-2334/14/423",30,YR,A,M,Y,65,KG,20140827,N,OT,CM,CM,EFAVIRENZ,Granuloma;Inflammation;Necrosis;Oedema;Paradoxical drug reaction;Skin lesion;Skin ulcer,104125102,HO,,,104125102,1,201301,20130303,,,104125102,1,Mycobacterium ulcerans infection
10444858,104448586,6,F,20140903,20150109,20140910,20150119,EXP,,KE-GILEAD-2014-0114649,GILEAD,,38,YR,A,M,Y,,,20150119,N,MD,KE,KE,EFAVIRENZ,Anaemia;Aplasia pure red cell;Tuberculosis,104448586,HO,,,104448586,1,20140819,20140819,,,104448586,1,HIV infection
10467426,104674262,2,F,20140721,20150309,20140922,20150323,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21389200,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,,,20150323,N,CN,US,MW,EFAVIRENZ,Pleural effusion;Pneumonia,104674262,HO,,,104674262,1,20140717,20141009,,,104674262,1,HIV infection
10495696,104956963,3,F,20140902,20150309,20141003,20150312,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21391164,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,66,KG,20150312,N,OT,ZW,ZW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Retained products of conception,104956963,OT,,,104956963,1,20110531,,,,104956963,1,HIV infection
10514822,105148222,2,F,,20150210,20141013,20150217,EXP,,CA-ABBVIE-14P-028-1293603-00,ABBVIE,,,,,M,Y,,,20150217,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,105148222,OT,,,,,,,,,105148222,1,Product used for unknown indication
10514830,105148302,2,F,,20150210,20141013,20150217,EXP,,CA-ABBVIE-14P-028-1293605-00,ABBVIE,,,,,M,Y,,,20150217,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,105148302,OT,,,,,,,,,105148302,1,Product used for unknown indication
10517337,105173373,3,F,,20150210,20141014,20150217,EXP,,CA-ABBVIE-14P-028-1294092-00,ABBVIE,,54,YR,,M,Y,,,20150217,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,105173373,OT,,,,,,,,,105173373,1,Product used for unknown indication
10517572,105175722,2,F,,20150205,20141014,20150213,EXP,,CA-ABBVIE-14P-028-1294263-00,ABBVIE,"PFEFFER G, COTE H, MEZEI M, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009;73 (1):71-72.",52,YR,,M,Y,,,20150213,N,MD,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,105175722,OT,,,,,,,,,105175722,1,HIV infection
10523527,105235272,2,F,20141001,20150306,20141017,20150312,EXP,,MW-GILEAD-2014-0118743,GILEAD,,30,YR,A,M,Y,,,20150312,N,MD,MW,MW,EFAVIRENZ,Meningitis cryptococcal,105235272,HO,,,105235272,1,20140801,,,,105235272,1,HIV infection
10538399,105383994,4,F,20141001,20150115,20141023,20150123,EXP,,CA-GLAXOSMITHKLINE-A1087940A,GLAXOSMITHKLINE,,34,YR,,F,Y,,,20150123,N,CN,US,CA,Efavirenz,Abortion spontaneous;Exposure during pregnancy,105383994,OT,,,105383994,1,,20140916,,,105383994,1,HIV infection
10540025,105400253,3,F,20140127,20141013,20141024,20150211,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21347141,BRISTOL MYERS SQUIBB,,0,DY,,,Y,,,20150211,N,CN,US,MW,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly,105400253,OT,,,105400253,1,20130522,20131022,,,105400253,1,Antiretroviral therapy
10544285,105442853,3,F,20141001,20150115,20141023,20150126,EXP,,A1087940A,VIIV,,34,YR,,F,N,,,20150122,N,PH,CA,,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy;Maternal exposure during pregnancy;Pregnancy;Rash,105442853,OT,105442853,HP,105442853,2,,20140916,,,105442853,1,HIV infection
10546081,105460815,5,F,20140926,20150128,20141027,20150202,EXP,,UG-GILEAD-2014-0119476,GILEAD,,42,YR,A,M,Y,59,KG,20150202,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Electrolyte imbalance;Malaria,105460815,LT,,,105460815,1,20140804,,,,105460815,1,HIV infection
10561657,105616574,4,F,20141016,20141119,20141103,20150128,EXP,,ZW-GILEAD-2014-0120772,GILEAD,,30,YR,A,F,Y,,,20150128,N,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma,105616574,HO,,,105616574,1,20130902,20141022,,,105616574,1,HIV infection
10590778,105907782,2,F,20141013,20141208,20141118,20150126,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21609235,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20150126,N,OT,UG,UG,EFAVIRENZ,Pulmonary tuberculosis;Tuberculosis,105907782,HO,,,105907782,1,20141008,20141011,,,105907782,1,HIV test
10627100,106271005,5,F,20140918,20150216,20141204,20150302,EXP,GB-MHRA-ADR 22779254,GB-BRISTOL-MYERS SQUIBB COMPANY-21657739,BRISTOL MYERS SQUIBB,,60,YR,,F,Y,,,20150302,N,CN,US,GB,SUSTIVA,Acute kidney injury,106271005,HO,,,,,,,,,106271005,1,Antiretroviral therapy
10627119,106271192,2,F,20141123,20150203,20141204,20150217,EXP,GB-MHRA-EYC 00117470,GB-BRISTOL-MYERS SQUIBB COMPANY-21664859,BRISTOL MYERS SQUIBB,,21,YR,,M,Y,68,KG,20150217,N,CN,US,GB,EFAVIRENZ,Hypoglycaemia;Overdose,106271192,OT,,,106271192,1,20140801,,,,106271192,1,HIV antibody positive
10636090,106360903,3,F,,20150205,20141205,20150212,EXP,,DE-GLAXOSMITHKLINE-DE2014GSK031123,GLAXOSMITHKLINE,,,,,F,Y,,,20150212,N,MD,DE,DE,SUSTIVA,Pancytopenia;Pyrexia,106360903,OT,,,106360903,1,2008,,,,106360903,1,HIV infection
10640227,106402272,2,F,,20150128,20141205,20150212,EXP,,2014HINOTH1036,HETERO,,35,WK,,M,N,,,20150210,N,,MW,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Accessory auricle;Foetal exposure during pregnancy;Premature baby,106402272,HO,106402272,FGN,106402272,1,20110608,,,,106402272,1,HIV infection
10641652,106416524,4,F,20141117,20150112,20141209,20150120,EXP,,KE-GILEAD-2014-0125579,GILEAD,,42,YR,A,F,Y,,,20150120,N,MD,KE,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,106416524,HO,,,106416524,1,20141110,20141114,,,106416524,1,HIV infection
10641727,106417273,3,F,20140918,20150113,20141209,20150119,EXP,,GB-ABBVIE-14P-167-1315688-00,ABBVIE,,60,YR,,F,Y,,,20150119,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,106417273,OT,,,,,,,,,106417273,1,Antiretroviral therapy
10642361,106423613,3,F,,20150205,20141208,20150218,EXP,,DE2014GSK031123,VIIV,,44,YR,,F,N,,,20150212,N,OT,DE,,SUSTIVA,Pancytopenia;Pyrexia,106423613,OT,106423613,HP,106423613,1,2008,,,,106423613,1,HIV infection
10655109,106551093,3,F,20141116,20150112,20141216,20150127,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-21680202,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20150127,N,MD,KE,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,106551093,HO,,,106551093,1,20141110,20141114,,,106551093,1,HIV infection
10659271,106592713,3,F,20111203,20150127,20141217,20150204,EXP,,AR-ABBVIE-14P-007-1321736-00,ABBVIE,,,,N,M,Y,,,20150204,N,OT,COUNTRY NOT SPECIFIED,AR,EFAVIRENZ,Foetal exposure during pregnancy;Plagiocephaly,106592713,OT,,,,,,,,,106592713,1,Maternal exposure timing unspecified
10662531,106625312,2,F,20131003,20141223,20141218,20150113,EXP,,US-BMSGILMSD-2014-0127745,GILEAD,,23,YR,A,F,Y,,,20150113,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,106625312,1,20140620,,,,106625312,1,HIV infection
10662826,106628263,3,F,20140620,20150122,20141218,20150310,EXP,,US-GILEAD-2014-0127543,GILEAD,,,,N,F,Y,3.1,KG,20150310,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Foetal exposure during pregnancy;Foetal malformation,106628263,CA,,,106628263,1,20140620,20140710,,,106628263,1,HIV infection
10674577,106745774,4,F,20141212,20150206,20141224,20150213,EXP,,TH-GILEAD-2014-0128093,GILEAD,,40,YR,A,M,Y,49.5,KG,20150213,N,MD,TH,TH,EFAVIRENZ,Hepatitis alcoholic,106745774,OT,,,106745774,1,20081121,,,,106745774,1,HIV infection
10683707,106837072,2,F,20140918,20150113,20141230,20150119,EXP,,GB-ABBVIE-14P-167-1326700-00,ABBVIE,,60,YR,,F,Y,,,20150119,N,PH,GB,GB,EFAVIRENZ,Acute kidney injury,106837072,HO,,,,,,,,,106837072,1,Antiretroviral therapy
10685908,106859083,3,F,20141211,20150112,20141231,20150127,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-003489,BRISTOL MYERS SQUIBB,,34,YR,,M,Y,58.4,KG,20150127,N,CN,US,MW,EFAVIRENZ,Bacterial sepsis;Candida infection,106859083,HO,,,106859083,1,20140505,,,,106859083,1,Antiretroviral therapy
10687390,106873902,2,F,,20150128,20141230,20150212,EXP,,2014HINOTH1083,HETERO,,39,WK,,M,N,3.1,KG,20150210,N,OT,AR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Maternal drugs affecting foetus;Plagiocephaly,106873902,CA,106873902,HP,,,,,,,106873902,1,HIV infection
10688669,106886692,2,F,,20150106,20150102,20150109,EXP,,FR-BMSGILMSD-2014-0129528,GILEAD,,44,YR,A,M,Y,,,20150109,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Off label use,,,,,,,,,,,106886692,1,Product used for unknown indication
10688847,106888472,2,F,20140204,20141218,20150103,20150103,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-20206934,BRISTOL MYERS SQUIBB,,62,YR,,M,Y,,,20150103,N,CN,US,KE,EFAVIRENZ,Drug-induced liver injury;Enteritis,106888472,OT,,,106888472,1,20140114,20140204,,,106888472,1,HIV infection
10691044,106910441,1,I,,20141208,20150105,20150105,PER,,US-009507513-1412USA006569,MERCK,,34,YR,,F,Y,,,20150105,N,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,,,,,,,106910441,1,Product used for unknown indication
10691165,106911651,1,I,,20141229,20150105,20150105,EXP,,US-BMSGILMSD-2014-0129482,GILEAD,,38,YR,A,M,Y,,,20150105,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Burkitt's lymphoma;Diffuse large B-cell lymphoma;Non-Hodgkin's lymphoma,106911651,OT,,,,,,,,,106911651,1,Product used for unknown indication
10692012,106920121,1,I,,20141224,20150106,20150106,EXP,,FR-CIPLA LTD.-2014FR03020,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150106,N,MD,FR,FR,Efavirenz,Virologic failure,106920121,OT,,,,,,,,,106920121,1,HIV infection
10692105,106921051,1,I,,20141224,20150106,20150106,EXP,,FR-CIPLA LTD.-2014FR03001,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN MA, SOGNI P ET.AL.. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150106,N,OT,FR,FR,Efavirenz,Cerebral haemorrhage;Immune thrombocytopenic purpura,106921051,DE,,,,,,,,,106921051,1,HIV infection
10692416,106924162,2,F,20141218,20150213,20150106,20150227,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-005557,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,59,KG,20150227,N,CN,MW,MW,EFAVIRENZ,Pneumonia bacterial,106924162,OT,,,106924162,1,20140513,20141218,,,106924162,1,HIV infection
10692957,106929572,2,F,,20150106,20150106,20150113,EXP,,FR-BMSGILMSD-2014-0129408,GILEAD,,40,YR,A,F,Y,,,20150113,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Off label use,,,,,,,,,,,106929572,1,Product used for unknown indication
10696879,106968791,1,I,,20141224,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03002,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN MA, SOGNI P ET.AL.. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768-1776",,,,,Y,,,20150108,N,OT,FR,FR,Efavirenz,Upper gastrointestinal haemorrhage,106968791,DE,,,,,,,,,106968791,1,HIV infection
10696905,106969051,1,I,,20141224,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03008,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. HIV/AIDS. 2014;59:1768 TO 1776",,,,,Y,,,20150108,N,OT,FR,FR,Efavirenz,Thrombocytopenia,106969051,OT,,,,,,,,,106969051,1,HIV infection
10696906,106969061,1,I,,20141224,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03029,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. CID. 2014;59:1768-1776",,,,,Y,,,20150108,N,MD,FR,FR,Efavirenz,Disease recurrence;Hepatitis C,106969061,OT,,,,,,,,,106969061,1,HIV infection
10697107,106971071,1,I,,20141224,20150108,20150108,EXP,,FR-CIPLA LTD.-2014FR03030,CIPLA,"COTTE L, BRAUN J, LASCOUX-COMBE C, VINCENT C, VALANTIN M, SOGNI P, LACOMBE K, NEAU D, AUMAITRE H, BATISSE D, DE TRUCHIS P, GERVAIS A, MICHELET C, MORLAT P, VITTECOQ D, ROSA I, BERTUCCI I, ET AL. TELAPREVIR FOR HIV/HEPATITIS C VIRUS-COINFECTED PATIENTS FAILING TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN (ANRS HC26 TELAPREVIH): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL. CID. 2014;59:1768-1776",,,,,Y,,,20150108,N,MD,FR,FR,Efavirenz,Psychiatric decompensation,106971071,OT,,,,,,,,,106971071,1,HIV infection
10697687,106976873,3,F,20101206,20150202,20150108,20150210,EXP,,KR-ABBVIE-11P-090-0725464-00,ABBVIE,,,,,M,Y,,,20150210,N,MD,COUNTRY NOT SPECIFIED,KR,EFAVIRENZ,Anaemia;Cytopenia,106976873,OT,,,106976873,1,20100524,20101205,,,106976873,1,Product used for unknown indication
10702684,107026842,2,F,20140530,20150203,20150109,20150217,EXP,,HT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-006382,BRISTOL MYERS SQUIBB,,51,YR,,F,Y,64,KG,20150217,N,CN,US,HT,EFAVIRENZ,Anaemia;Atrial fibrillation;Congestive cardiomyopathy;Diarrhoea;Sepsis,107026842,OT,,,107026842,1,20140526,20141205,,,107026842,1,Tuberculosis
10705738,107057382,2,F,20141210,20150112,20150112,20150115,EXP,,UG-GLAXOSMITHKLINE-UG2014GSK046238,GLAXOSMITHKLINE,,,,,,Y,,,20150115,N,MD,UG,UG,EFAVIRENZ,Blood bilirubin increased;Blood creatinine increased;Bronchopneumonia;Candida infection;Haemoptysis;Hepatotoxicity;Neutropenia,107057382,DE,,,107057382,1,20141217,20141224,,,,,
10706302,107063022,2,F,20141210,20150112,20150109,20150115,EXP,,UG2014GSK046238,VIIV,,37,YR,,M,N,,,20150114,N,MD,UG,,EFAVIRENZ (EFAVIRENZ),Blood creatinine increased;Blood pressure decreased;Bronchopneumonia;Decreased appetite;Dehydration;Haemoglobin decreased;Haemoptysis;Heart rate increased;Hepatomegaly;Hepatotoxicity;Jaundice;Neutropenia;Oesophageal candidiasis;Oral candidiasis;Pallor;Pharyngeal ulceration;Platelet count decreased;Splenomegaly;Wound complication,107063022,DE,107063022,FGN,107063022,1,20141217,20141224,,,,,
10707713,107077131,1,I,,20150102,20150113,20150113,EXP,,US-GILEAD-2015-0130366,GILEAD,,75,YR,E,M,Y,,,20150113,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood glucose decreased;Blood pressure inadequately controlled;Diabetes mellitus;Haemoglobin decreased;Infected skin ulcer;Localised infection;Osteomyelitis;Speech disorder,107077131,OT,,,,,,,,,107077131,1,HIV infection
10709127,107091271,1,I,20141112,20150109,20150114,20150114,EXP,,TH-009507513-1501THA002949,MERCK,,47,YR,,M,Y,,,20150114,N,MD,TH,TH,EFAVIRENZ,Overdose,107091271,DE,,,107091271,1,20141015,20141112,,,107091271,1,Hepatitis C
10709794,107097941,1,I,20140121,20140131,20150114,20150114,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-20173589,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,40.8,KG,20150114,N,CN,US,ZW,EFAVIRENZ,Decreased appetite;Dehydration;Diarrhoea;Leukopenia;Myelodysplastic syndrome;Pancytopenia;Vomiting;Weight decreased,107097941,LT,,,107097941,1,20130910,,,,107097941,1,HIV infection
10713649,107136491,1,I,,20141231,20150115,20150115,EXP,,US-CIPLA LTD.-2015US00256,CIPLA,"DORSEY G, NATUREEBA P, ADES V, LUWEDDE F, MWESIGWA J, PLENTY A ET.AL.. LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL TREATMENT (ART) VERSUS EFAVIRENZ-BASED ART FOR THE PREVENTION OF MALARIA AMONG HIV-INFECTED PREGNANT WOMEN. THE JOURNAL OF INFECTIOUS DISEASES. 2014;210:1938-45",,,,,Y,,,20150115,N,OT,US,US,Efavirenz,Abortion spontaneous,107136491,OT,,,,,,,,,107136491,1,HIV infection
10717844,107178442,2,F,20141117,20150210,20150116,20150213,EXP,,RW-GILEAD-2015-0130621,GILEAD,,,,,F,Y,,,20150213,N,OT,RW,RW,EFAVIRENZ,Bone tuberculosis,107178442,OT,,,107178442,1,20140813,20141117,,,107178442,1,HIV infection
10718212,107182121,1,I,,20141219,20150118,20150118,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-005107,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150118,N,CN,UG,UG,EFAVIRENZ,HIV associated nephropathy;Sputum abnormal,107182121,DE,,,107182121,1,20141127,20141202,,,107182121,1,HIV infection
10719292,107192921,1,I,,20150116,20150119,20150119,EXP,,CA-ROCHE-1522743,ROCHE,,54,YR,,M,Y,,,20150119,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,107192921,OT,,,,,,,,,107192921,1,Product used for unknown indication
10721346,107213461,1,I,,20150113,20150119,20150119,EXP,,US-BMSGILMSD-2015-0132183,GILEAD,,67,YR,E,M,Y,,,20150119,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bladder cancer;Prostate cancer,107213461,OT,,,,,,,,,107213461,1,HIV infection
10722382,107223822,2,F,20141121,20150203,20150119,20150211,EXP,,UG-GILEAD-2015-0132050,GILEAD,,55,YR,A,F,Y,55,KG,20150211,N,MD,UG,UG,EFAVIRENZ,Urinary tract infection,107223822,HO,,,107223822,1,20121115,,,,107223822,1,HIV infection
10723036,107230361,1,I,,20141202,20150114,20150114,EXP,,2014HINLIT1048,HETERO,,51,YR,,F,N,,,20141215,N,OT,IN,,EFAVIRENZ,Acute kidney injury;Blood glucose decreased;Blood pressure decreased;Cerebral atrophy;Depressed level of consciousness;Drug interaction;Heart rate increased;Hypophagia;Metabolic acidosis;Pallor;Vomiting,107230361,HO,107230361,HP,,,,,,,107230361,1,HIV infection
10723666,107236661,1,I,,20150114,20150120,20150120,EXP,,US-BMSGILMSD-2015-0132386,GILEAD,,62,YR,A,M,Y,,,20150120,N,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise,107236661,HO,,,,,,,,,107236661,1,HIV infection
10724570,107245701,1,I,,20150108,20150120,20150120,EXP,,IR-MYLANLABS-2015M1000677,MYLAN,"AHMADINEJAD Z, GHETMIRI Z, RASOOLINEJAD M. CYTOMEGALOVIRUS RETINITIS AFTER INITIATION OF ANTIRETROVIRAL THERAPY. ACTA-MED-IRAN 2013; 51(10) 730-732",,,,,Y,,,20150120,N,OT,IR,IR,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107245701,HO,,,,,,,,,107245701,1,HIV infection
10724794,107247942,2,F,20141207,20150114,20150120,20150129,EXP,,ZW-009507513-1501ZWE006327,MERCK,,43,YR,,F,Y,,,20150129,N,CN,US,ZW,EFAVIRENZ,Death,107247942,DE,,,107247942,1,20140930,,,,107247942,1,Antiretroviral therapy
10725381,107253811,1,I,,20150120,20150121,20150121,EXP,,CA-ROCHE-1523511,ROCHE,,54,YR,,M,Y,,,20150121,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,107253811,OT,,,,,,,,,107253811,1,Product used for unknown indication
10725409,107254091,1,I,,20150116,20150121,20150121,EXP,,CA-ROCHE-1522668,ROCHE,REPORTER KNOWN TO HEALTH AUTHORITY. UNKNOWN. UNKNOWN ;:-.,44,YR,,M,Y,,,20150121,N,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,107254091,HO,,,,,,,,,107254091,1,Depression
10727066,107270661,1,I,,20150114,20150121,20150121,EXP,,US-BMSGILMSD-2015-0132357,GILEAD,,53,YR,A,M,Y,,,20150121,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Asthenia;Diarrhoea;Hepatitis C;Weight decreased,107270661,OT,,,,,,,,,107270661,1,Product used for unknown indication
10729305,107293051,1,I,,20150109,20150122,20150122,EXP,,PT-MYLANLABS-2015M1000957,MYLAN,"ALMEIDA FERREIRA M, CARVALHO AC, SILVA SV, FRANCA M, BORGES F. TWO ENDOCRINE DISEASES IN ONE CASE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. HIV-AIDS-REV 2014; 13(2) 60-62",,,,,Y,,,20150122,N,OT,PT,PT,EFAVIRENZ,Basedow's disease;Diabetic ketoacidosis;Gastrointestinal disorder;Immune reconstitution inflammatory syndrome;Neurotoxicity;Skin disorder;Type 1 diabetes mellitus,107293051,HO,,,,,,,,,107293051,4,Acquired immunodeficiency syndrome
10729425,107294252,2,F,20141031,20150112,20150122,20150127,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-001948,BRISTOL MYERS SQUIBB,,55,YR,,F,Y,55,KG,20150127,N,CN,US,UG,EFAVIRENZ,Diabetes mellitus;Pelvic inflammatory disease;Urinary tract infection,107294252,HO,,,107294252,1,20121115,,,,107294252,1,HIV infection
10729806,107298061,1,I,20141031,20150112,20150122,20150122,EXP,,UG-GILEAD-2015-0131848,GILEAD,,55,YR,A,F,Y,55,KG,20150122,N,MD,UG,UG,EFAVIRENZ,Urinary tract infection,107298061,HO,,,107298061,1,20121115,,,,107298061,1,HIV infection
10730454,107304541,1,I,,20150112,20150122,20150122,EXP,,CA-APOTEX-2015AP005292,APOTEX,,52,YR,,M,Y,,,20150122,N,OT,CA,CA,EFAVIRENZ,Nephropathy toxic,107304541,OT,,,,,,,,,107304541,1,Hypercholesterolaemia
10731170,107311701,1,I,20141128,20150116,20150122,20150122,EXP,,US-GILEAD-2015-0132837,GILEAD,,66,YR,E,M,Y,,,20150122,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,107311701,OT,,,,,,,,,107311701,1,HIV infection
10732324,107323241,1,I,199809,20150108,20150123,20150123,EXP,,KP-CIPLA LTD.-2015KP00442,CIPLA,"CHO Y.K., KIM B.R., KIM J.E. AND SUNG H. LONG-TERM FOLLOW UP OF HIV-1-INFECTED KOREAN HAEMOPHILIACS, AFTER INFECTION FROM A COMMON SOURCE OF VIRUS HAEMOPHILIA. HAEMOPHILIA. 2015;21:E1-E11",,,,,Y,,,20150123,N,OT,COUNTRY NOT SPECIFIED,KP,Efavirenz,Drug resistance;Gastroenteritis;Haematoma;Hepatic cirrhosis;Joint arthroplasty;Oral candidiasis;Splenomegaly;Weight decreased,107323241,OT,,,107323241,1,201007,,,,,,
10733012,107330121,1,I,,20150116,20150123,20150123,EXP,,US-BMSGILMSD-2015-0132942,GILEAD,,38,YR,A,M,Y,,,20150123,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,AIDS dementia complex;Myelopathy,107330121,HO,,,,,,,,,107330121,1,HIV infection
10733140,107331402,2,F,20150112,20150127,20150120,20150202,EXP,,BR2014GSK047462,VIIV,,3,WK,,F,N,,,20150129,N,MD,BR,,EFAVIRENZ (EFAVIRENZ),Anaemia,107331402,RI,107331402,HP,107331402,1,20141016,,,,,,
10734045,107340451,1,I,20140725,20150119,20150123,20150123,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK007354,GLAXOSMITHKLINE,,40,YR,,M,Y,48,KG,20150123,N,MD,CN,CN,Efavirenz,Pruritus;Rash,107340451,HO,,,107340451,1,20140514,20140725,,,107340451,1,Acquired immunodeficiency syndrome
10734046,107340461,1,I,20140901,20150119,20150123,20150123,EXP,,CN-GLAXOSMITHKLINE INC.-CN2015GSK007360,GLAXOSMITHKLINE,,57,YR,,F,Y,60,KG,20150123,N,MD,CN,CN,Efavirenz,Hepatocellular injury,107340461,OT,,,107340461,1,20140305,20140811,,,107340461,1,Acquired immunodeficiency syndrome
10734286,107342863,3,F,20141205,20150209,20150123,20150213,EXP,,ZA-GILEAD-2014-0128682,GILEAD,,47,YR,A,M,Y,110.5,KG,20150213,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Pneumonia,107342863,DE,,,107342863,1,20140709,20141204,,,107342863,1,HIV infection
10739573,107395731,1,I,,20150122,20150126,20150126,EXP,,CA-ROCHE-1524948,ROCHE,,54,YR,,M,Y,,,20150127,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,107395731,OT,,,,,,,,,107395731,1,Product used for unknown indication
10740036,107400361,1,I,,20140605,20150127,20150127,EXP,,"PT-AUROBINDO PHARMA,UNIPESSOAL LIMITADA-AUR-APL-2014-06500",AUROBINDO,,36,YR,,M,Y,,,20150127,N,OT,PT,PT,EFAVIRENZ,Gastrointestinal disorder;Immune reconstitution inflammatory syndrome;Neurotoxicity;Skin disorder,107400361,OT,,,,,,,,,107400361,1,Acquired immunodeficiency syndrome
10740435,107404351,1,I,,20150112,20150127,20150127,EXP,,TZ-CIPLA LTD.-2015TZ00564,CIPLA,"DAUDI R. MAVURA, E. JOHN MASENGA, ELI MINJA, HENNING GROSSMANN, JOHN A. CRUMP AND JOHN A. BARTLETT. INITIATION OF ANTIRETROVIRAL THERAPY IN HIV INFECTED ADULTS WITH SKIN COMPLAINTS IN NORTHERN TANZANIA. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2015;54:68 TO 73",,,,,Y,,,20150127,N,OT,TZ,TZ,Efavirenz,Kaposi's sarcoma,107404351,DE,,,,,,,,,107404351,1,HIV infection
10740490,107404901,1,I,,20150112,20150127,20150127,EXP,,TZ-CIPLA LTD.-2015TZ00567,CIPLA,"DAUDI R. MAVURA, E. JOHN MASENGA, ELI MINJA, HENNING GROSSMANN, JOHN A. CRUMP AND JOHN A. BARTLETT. INITIATION OF ANTIRETROVIRAL THERAPY IN HIV INFECTED ADULTS WITH SKIN COMPLAINTS IN NORTHERN TANZANIA. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2015;54:68 TO 73",,,,,Y,,,20150127,N,OT,TZ,TZ,Efavirenz,Anaemia,107404901,DE,,,,,,,,,107404901,1,HIV infection
10740927,107409271,1,I,,20150119,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00401,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS NCVIRAPINE^S EPITAPH?. PLOS ONE. 2014;9(4)",,,,F,Y,,,20150127,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash generalised;Rash maculo-papular;Rash pruritic,107409271,OT,,,,,,,,,107409271,1,Antiretroviral therapy
10740930,107409301,1,I,,20150119,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00404,AUROBINDO,SARFO FS ET AL. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS: NCVIRAPINE^S EPITAPH?. PLOS ONE. 2014;4,,,,F,Y,,,20150127,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107409301,OT,,,,,,,,,107409301,1,Antiretroviral therapy
10741432,107414321,1,I,,20150119,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00402,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST-AFRICANS: NEVIRAPINE^S EPITAPH?. PLOS ONE. 2015;1534:77",,,,F,Y,,,20150127,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107414321,OT,,,,,,,,,107414321,1,HIV infection
10743376,107433761,1,I,,20150119,20150127,20150127,EXP,,GH-AUROBINDO-AUR-APL-2015-00405,AUROBINDO,"SARFO FS, ET AL.. INCIDENCE AND DETERMINANTS OF NEVIRAPINE AND EFAVIRENZ-RELATED SKIN RASHES IN WEST AFRICANS: NEVIRAPINE^S EPITAPH?. PLOS ONE. 2014;9(4)",,,,M,Y,,,20150127,N,OT,GH,GH,Efavirenz,Drug hypersensitivity;Mucosal ulceration;Rash;Rash maculo-papular;Rash pruritic,107433761,OT,,,,,,,,,107433761,1,HIV infection
10744465,107444651,1,I,20140901,20150119,20150126,20150126,EXP,,CN2015GSK007360,VIIV,,58,YR,,F,N,60.0,KG,20150123,N,OT,CN,,EFAVIRENZ,Hepatocellular injury,107444651,OT,107444651,FGN,107444651,1,20140305,20140811,,,107444651,1,Acquired immunodeficiency syndrome
10744520,107445201,1,I,20140725,20150119,20150126,20150126,EXP,,CN2015GSK007354,VIIV,,40,YR,,M,N,48.0,KG,20150123,N,MD,CN,,EFAVIRENZ,Pruritus;Rash,107445201,HO,107445201,FGN,107445201,1,20140514,20140625,,,107445201,1,Acquired immunodeficiency syndrome
10744935,107449351,1,I,,20150121,20150128,20150128,EXP,,US-BMSGILMSD-2015-0133782,GILEAD,,55,YR,A,M,Y,,,20150128,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Oesophageal stenosis;Weight decreased,107449351,HO,,,,,,,,,107449351,1,Product used for unknown indication
10746135,107461351,1,I,20141117,20150121,20150128,20150128,EXP,,BW-BMSGILMSD-2015-0133689,GILEAD,,38,YR,A,F,Y,,,20150128,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,107461351,OT,,,107461351,1,20120611,,,,107461351,1,HIV infection
10746595,107465951,1,I,20140817,20150119,20150128,20150128,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK010273,GLAXOSMITHKLINE,,61,YR,,M,Y,52,KG,20150128,N,MD,CN,CN,Efavirenz,Alcohol poisoning;Asthenia;Dizziness,107465951,OT,,,107465951,1,20140814,20140825,,,107465951,1,Acquired immunodeficiency syndrome
10748230,107482301,1,I,,20150114,20150129,20150129,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-004623,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150129,N,CN,US,ZW,EFAVIRENZ,Death,107482301,DE,,,107482301,1,20140930,,,,107482301,1,Antiretroviral therapy
10749633,107496331,1,I,,20150116,20150129,20150129,EXP,,NL-MYLANLABS-2015M1002098,MYLAN,"SCHOUTEN JN, VAN DER ENDE ME, KOETER T, ROSSING HH, KOMUTA M, VERHEIJ J, ET AL. RISK FACTORS AND OUTCOME OF HIV-ASSOCIATED IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION. ALIMENT-PHARMACOL-THER 2012; 36(9) 875-85",,,,,Y,,,20150129,N,OT,NL,NL,EFAVIRENZ,Oesophageal varices haemorrhage;Portal hypertension,107496331,OT,,,,,,,,,107496331,1,HIV infection
10749800,107498001,1,I,,20150119,20150129,20150129,EXP,,CN-GLAXOSMITHKLINE-CN2015011033,GLAXOSMITHKLINE,,,,,,Y,,,20150129,N,OT,CN,CN,Efavirenz,Pruritus;Rash,107498001,HO,,,107498001,1,20140514,20140725,,,107498001,1,Acquired immunodeficiency syndrome
10749818,107498182,2,F,201211,20150312,20150129,20150319,EXP,,JP-GLAXOSMITHKLINE-JP2015JPN009992,GLAXOSMITHKLINE,,37,YR,,M,Y,,,20150319,N,MD,JP,JP,Efavirenz,Abulia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Hyperreflexia;JC virus infection;Lethargy;Locked-in syndrome;Progressive multifocal leukoencephalopathy;Pyrexia,107498182,DE,,,,,,,,,107498182,4,HIV infection
10749832,107498321,1,I,20140901,20150119,20150129,20150129,EXP,,CN-GLAXOSMITHKLINE-CN2015010531,GLAXOSMITHKLINE,,,,,,Y,,,20150129,N,OT,CN,CN,Efavirenz,Hepatocellular injury,107498321,OT,,,107498321,1,20140305,20140911,,,107498321,1,Acquired immunodeficiency syndrome
10749941,107499411,1,I,20140903,20150126,20150129,20150129,EXP,,US-BMSGILMSD-2015-0134293,GILEAD,,57,YR,A,M,Y,,,20150129,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,107499411,OT,,,,,,,,,107499411,1,Acquired immunodeficiency syndrome
10750185,107501851,1,I,20140103,20150116,20150129,20150129,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-004640,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,73,KG,20150129,N,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute kidney injury;Anaemia;Bacteraemia;Disease progression,107501851,OT,,,107501851,1,20130725,20131106,,,107501851,1,Antiretroviral therapy
10751711,107517113,3,F,20141104,20150205,20150130,20150213,EXP,,MW-ABBVIE-15P-100-1336374-00,ABBVIE,,31,YR,,F,Y,49,KG,20150213,N,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Abortion incomplete,107517113,HO,,,107517113,1,20141014,20141014,,,107517113,1,HIV infection
10752198,107521981,1,I,1983,20150121,20150130,20150130,EXP,,US-GILEAD-2015-0133756,GILEAD,,64,YR,A,M,Y,,,20150130,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Cognitive disorder;Gait disturbance;Hearing impaired;Malaise;Myocardial infarction;Nausea;Neoplasm malignant;Neuropathy peripheral;Pain;Spinal column injury;Visual impairment,107521981,OT,,,,,,,,,107521981,1,HIV infection
10752212,107522121,1,I,,20150126,20150130,20150130,EXP,,US-BMSGILMSD-2015-0134700,GILEAD,,41,YR,A,M,Y,,,20150130,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,107522121,DE,,,,,,,,,107522121,1,HIV infection
10752478,107524781,1,I,,20150123,20150130,20150130,EXP,,US-BMSGILMSD-2015-0134568,GILEAD,,52,YR,A,M,Y,,,20150130,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,107524781,OT,,,,,,,,,107524781,1,HIV infection
10752506,107525061,1,I,,20150126,20150130,20150130,EXP,,US-GILEAD-2015-0134483,GILEAD,,45,YR,A,F,Y,,,20150130,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness,107525061,HO,,,,,,,,,107525061,1,HIV infection
10753551,107535511,1,I,,20150113,20150129,20150129,EXP,,2015HINLIT0016,HETERO,,,,A,,N,,,20150127,N,OT,GB,,EFAVIRENZ,Neurotoxicity,107535511,OT,107535511,FGN,,,,,,,107535511,1,Antiretroviral therapy
10753572,107535721,1,I,,20150113,20150129,20150129,EXP,,2015HINLIT0022,HETERO,,34,YR,,F,N,,,20150127,N,OT,IR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107535721,OT,107535721,LIT,,,,,,,107535721,1,HIV infection
10753871,107538711,1,I,20140817,20150119,20150129,20150129,EXP,,CN2015GSK010273,VIIV,,62,YR,,M,N,52.0,KG,20150128,N,MD,CN,,EFAVIRENZ,Alcohol poisoning;Asthenia;Dizziness,107538711,OT,107538711,HP,107538711,1,20140814,20140825,,,107538711,1,Acquired immunodeficiency syndrome
10753895,107538952,2,F,20150122,20150130,20150129,20150212,EXP,,JP2015JPN008882,VIIV,,60,YR,,M,N,,,20150209,N,MD,JP,,STOCRIN (EFAVIRENZ),Cerebral haemorrhage,107538952,HO,107538952,FGN,,,,,,,107538952,1,HIV infection
10756420,107564201,1,I,,20150126,20150202,20150202,EXP,,US-GILEAD-2015-0134778,GILEAD,,31,YR,A,M,Y,,,20150202,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abscess limb,107564201,HO,,,,,,,,,107564201,1,HIV infection
10757184,107571843,3,F,201211,20150312,20150130,20150320,EXP,,JP2015JPN009992,VIIV,,37,YR,,M,N,,,20150318,N,OT,JP,,EFAVIRENZ,Abulia;Bradykinesia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Haemophilic arthropathy;Hyperreflexia;Immune reconstitution inflammatory syndrome;JC virus infection;Lethargy;Locked-in syndrome;Masked facies;Progressive multifocal leukoencephalopathy;Pyrexia;Treatment noncompliance,107571843,HO,107571843,FGN,,,,,,,107571843,4,HIV infection
10757327,107573271,1,I,20140901,20150119,20150130,20150130,EXP,,CN2015010531,VIIV,,58,YR,,F,N,69,KG,20150128,N,OT,CN,,EFAVIRENZ (EFAVIRENZ),Hepatocellular injury,107573271,OT,107573271,HP,107573271,1,20140305,20140911,,,107573271,1,Acquired immunodeficiency syndrome
10757350,107573501,1,I,,20150126,20150203,20150203,EXP,,BR-ROCHE-1527677,ROCHE,"RAMOS G, GUARALDO L, JAPIASSU A AND BOZZA F COMPARISON OF TWO DATABASES TO DETECT POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN PRESCRIPTIONS OF HIV/AIDS PATIENTS IN CRITICAL CARE. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 2015;40(1):63-67.",,,,,Y,,,20150203,N,OT,BR,BR,EFAVIRENZ,Drug interaction,107573501,OT,,,,,,,,,107573501,1,Product used for unknown indication
10757353,107573531,1,I,,20150119,20150130,20150130,EXP,,CN20154011033,VIIV,,40,YR,,M,N,48.0,KG,20150128,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Pruritus;Rash;Scratch,107573531,HO,107573531,FGN,107573531,1,20140514,20140725,,,107573531,1,Acquired immunodeficiency syndrome
10759720,107597201,1,I,20141201,20150128,20150203,20150203,EXP,,FR-GLAXOSMITHKLINE-FR2015GSK012400,GLAXOSMITHKLINE,,38,YR,,F,Y,,,20150203,N,OT,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107597201,OT,,,107597201,1,20131226,20141204,,,107597201,1,HIV infection
10759869,107598691,1,I,,20150128,20150203,20150203,EXP,,US-BMSGILMSD-2015-0134972,GILEAD,,70,YR,E,M,Y,,,20150203,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,107598691,OT,,,,,,,,,107598691,1,HIV infection
10762006,107620061,1,I,,20150128,20150204,20150204,EXP,,"IR-ROXANE LABORATORIES, INC.-2015-RO-00170RO",ROXANE,"AHMADINEJAD Z,GHETMIRI Z,RASOOLINEJAD M. CYTOMEGALOVIRUS RETINITIS AFTER INITIATION OF ANTIRETROVIRAL THERAPY. ACTA MEDICA IRANICA 2013;51:10:730-732.",34,YR,,F,Y,,,20150204,N,OT,COUNTRY NOT SPECIFIED,IR,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,107620061,HO,,,,,,,,,107620061,1,HIV infection
10763660,107636601,1,I,2002,20140721,20150204,20150204,EXP,,US-GLAXOSMITHKLINE-A1082147A,GLAXOSMITHKLINE,,,,,M,Y,,,20150204,N,CN,US,US,SUSTIVA,Burning sensation;Dry skin;Neuropathy peripheral;Pain;Sensory disturbance;Skin discolouration;Visual acuity reduced,,,,,107636601,1,1999,,,,107636601,1,HIV infection
10763906,107639063,3,F,20141119,20150305,20150204,20150312,EXP,,ZA-BMSGILMSD-2015-0135192,GILEAD,,29,YR,A,F,Y,,,20150312,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,107639063,OT,,,107639063,1,20140604,,,,107639063,1,HIV infection
10765471,107654711,1,I,,20150127,20150205,20150205,EXP,,GB-ABBVIE-15P-167-1339101-00,ABBVIE,,,,,,Y,,,20150205,N,OT,COUNTRY NOT SPECIFIED,GB,SUSTIVA,Foetal exposure during pregnancy;Ultrasound antenatal screen abnormal,107654711,OT,,,,,,,,,107654711,1,Maternal exposure timing unspecified
10767739,107677391,1,I,,20150202,20150205,20150205,EXP,,US-BMSGILMSD-2015-0135653,GILEAD,,43,YR,A,M,Y,,,20150205,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Nightmare;Wrist fracture,107677391,HO,,,,,,,,,107677391,1,HIV infection
10768484,107684842,2,F,20140102,20150324,20150206,20150331,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-19970813,BRISTOL MYERS SQUIBB,,73,YR,,M,Y,63,KG,20150331,N,CN,FR,FR,SUSTIVA,Delirium;Inappropriate antidiuretic hormone secretion,107684842,HO,,,107684842,1,20131022,,,,107684842,1,Metastatic malignant melanoma
10770130,107701301,1,I,20141116,20141202,20150206,20150206,EXP,,KE-009507513-1502KEN002532,MERCK,,42,YR,,F,Y,,,20150206,N,CN,US,KE,EFAVIRENZ,Cachexia;Death;Gastroenteritis;Oral candidiasis,107701301,LT,,,107701301,1,20141110,20141110,,,107701301,1,HIV infection
10775555,107755551,1,I,20141201,20150128,20150205,20150205,EXP,,FR2015GSK012400,VIIV,,38,YR,,F,N,,,20150203,N,OT,FR,,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107755551,OT,107755551,HP,107755551,1,20131225,20141204,,,107755551,1,HIV infection
10779918,107799181,1,I,20141024,20150130,20150206,20150206,EXP,,MW2015GSK014589,VIIV,,25,YR,,F,N,,,20150204,N,OT,MW,,SUSTIVA,Abortion spontaneous;Exposure during pregnancy;Pregnancy,107799181,OT,107799181,HP,107799181,1,20091123,20141024,,,107799181,1,HIV infection
10782797,107827971,1,I,,20150127,20150210,20150210,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006291,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150210,N,CN,GB,GB,EFAVIRENZ,Ultrasound antenatal screen abnormal,107827971,OT,,,107827971,1,20140916,20141031,,,107827971,1,Antiretroviral therapy
10783183,107831831,1,I,2014,20150204,20150210,20150210,EXP,,US-BMSGILMSD-2015-0136113,GILEAD,,48,YR,A,F,Y,,,20150210,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intestinal perforation,107831831,HO,,,,,,,,,107831831,1,HIV infection
10783185,107831851,1,I,,20150203,20150210,20150210,EXP,,US-BMSGILMSD-2015-0136133,GILEAD,,65,YR,E,F,Y,,,20150210,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Joint stiffness,107831851,HO,,,,,,,,,107831851,1,HIV infection
10783699,107836991,1,I,20141231,20150126,20150210,20150210,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006543,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,54.2,KG,20150210,N,CN,US,ZW,EFAVIRENZ,Anaemia;Dysfunctional uterine bleeding;Ovarian cyst,107836991,OT,,,107836991,1,20080630,,,,107836991,1,HIV infection
10783942,107839421,1,I,,20150202,20150210,20150210,EXP,,IN-AUROBINDO-AUR-APL-2015-01044,AUROBINDO,ANAND LINGESWARAN. ANTIRETROVIRAL TREATMENT INDUCED CATATONIA IN 16-YEAR-OLD BOY. JOURNAL OF PEDIATRIC NEUROSCIENCES. 2014;9(3):283-285,16,YR,,M,Y,,,20150210,N,OT,IN,IN,EFAVIRENZ TABLETS,Agitation;Catatonia;Drug withdrawal syndrome;Echopraxia;Grimacing;Mutism;Negativism;Poor quality sleep;Posturing,107839421,OT,,,,,,,,,107839421,1,Antiretroviral therapy
10784348,107843481,1,I,20141229,20150127,20150211,20150211,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006745,BRISTOL MYERS SQUIBB,,69,YR,,M,Y,,,20150211,N,CN,US,US,SUSTIVA,Prostate cancer,107843481,OT,,,107843481,1,2001,,,,107843481,1,HIV infection
10787567,107875671,1,I,20141201,20150128,20150212,20150212,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-005944,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20150212,N,CN,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,107875671,HO,,,107875671,1,20140731,20141204,,,107875671,1,HIV infection
10793812,107938121,1,I,20141024,20150130,20150213,20150213,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-008111,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,,,20150213,N,CN,MW,MW,EFAVIRENZ,Abortion spontaneous;Pregnancy,107938121,OT,,,107938121,1,20140805,20141024,,,107938121,1,HIV infection
10794428,107944281,1,I,20131101,20141205,20150213,20150213,EXP,,UG-GILEAD-2014-0126150,GILEAD,,29,YR,A,M,Y,64,KG,20150213,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Dyspnoea;Malaise;Peripheral swelling;Pyrexia;Septic shock;Skin hyperpigmentation;Vomiting,107944281,HO,,,107944281,1,20140409,,,,107944281,1,HIV infection
10803696,108036961,1,I,,20150210,20150217,20150217,EXP,,US-GLAXOSMITHKLINE-US2015GSK018734,GLAXOSMITHKLINE,"BOSSE KR, ET AL. ACUTE RENAL INJURY IN A 14-YEAR-OLD WITH HIV/AIDS AND TUBERCULOSIS. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2013;32;09:E380-E382",14,YR,,M,Y,,,20150217,N,OT,US,US,Efavirenz,Abdominal pain;Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Kidney enlargement;Lymphadenopathy;Nephropathy toxic;Neuropathy peripheral;Pyrexia;Tubulointerstitial nephritis;Vomiting,108036961,HO,,,,,,,,,108036961,1,HIV infection
10809294,108092941,1,I,20150208,,20150212,20150212,DIR,,,,,62,YR,,M,N,67.1,KG,20150211,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFORVIR,Acute kidney injury;Blood creatinine increased;Decreased appetite;Fanconi syndrome;Flank pain;Metabolic acidosis;Nephropathy toxic;Procedural nausea;Procedural vomiting;Renal tubular necrosis;Urine analysis abnormal,108092941,RI,108092941,HP,108092941,1,20150108,20150129,,,108092941,1,Hepatitis C
10811856,108118561,1,I,,20150127,20150212,20150212,EXP,,2015HINLIT0118,HETERO,,33,YR,,F,N,,,20150210,N,OT,NL,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Oesophageal varices haemorrhage;Portal hypertension,108118561,OT,108118561,HP,108118561,2,,,1095,DAY,108118561,1,HIV infection
10812049,108120491,1,I,,20150127,20150212,20150212,EXP,,2015HINLIT0114,HETERO,,29,YR,,M,N,,,20150210,N,OT,NL,,EFAVIRENZ (EFAVIRENZ),Pancytopenia;Portal hypertension,108120491,OT,108120491,LIT,108120491,3,,,5475,DAY,108120491,1,HIV infection
10816758,108167581,1,I,,20150204,20150218,20150218,EXP,,NL-MYLANLABS-2015M1005167,MYLAN,"ROKX C, VERBON A, RIJNDERS BJA. SUCCESSFUL SWITCH TO RILPIVIRINE/TENOFOVIR/EMTRICITABINE IN HIV-1-INFECTED PATIENTS WITH AN ISOLATED K103N MUTATION ACQUIRED DURING PRIOR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY. HIV-MED 2014; 15(10):611-614.",,,,,Y,,,20150218,N,MD,NL,NL,EFAVIRENZ,Pathogen resistance;Treatment failure;Virologic failure,108167581,OT,,,,,,,,,108167581,1,HIV infection
10817201,108172011,1,I,20150128,20150203,20150218,20150218,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-007395,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,101,KG,20150218,N,OT,ZW,ZW,EFAVIRENZ,Hepatotoxicity,108172011,LT,,,108172011,1,20091119,20130515,,,108172011,1,HIV infection
10820750,108207501,1,I,20131220,20131230,20150218,20150218,PER,,US-CELGENEUS-163-21880-14010066,CELGENE,,62,YR,,M,Y,178,KG,20150218,N,OT,US,US,SUSTIVA,Joint swelling,108207501,OT,,,108207501,1,200811,,,,108207501,1,Plasma cell myeloma
10833190,108331901,1,I,,20150212,20150219,20150219,EXP,,US-BMSGILMSD-2015-0137763,GILEAD,,61,YR,A,M,Y,,,20150219,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lymphoma;Neoplasm malignant,108331901,OT,,,,,,,,,108331901,1,HIV infection
10833295,108332951,1,I,,20150210,20150219,20150219,EXP,,US-GILEAD-2015-0137401,GILEAD,,45,YR,A,M,Y,,,20150219,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Pathogen resistance,108332951,OT,,,,,,,,,108332951,1,HIV infection
10833511,108335111,1,I,20141126,20150209,20150219,20150219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-009581,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,111,KG,20150219,N,OT,ZA,ZA,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Kaposi's sarcoma;Pleural effusion,108335111,OT,,,108335111,1,20140709,20141026,,,108335111,1,Kaposi's sarcoma
10846551,108465511,1,I,,20150208,20150220,20150220,EXP,,NG-GLAXOSMITHKLINE-NG2015GSK023178,GLAXOSMITHKLINE,,,,N,F,Y,,,20150220,N,OT,NG,NG,Efavirenz,Cleft palate;Foetal exposure during pregnancy;Live birth,108465511,OT,,,,,,,,,108465511,1,HIV infection
10846561,108465611,1,I,,20150208,20150220,20150220,EXP,,NG-GLAXOSMITHKLINE-NG2015GSK023192,GLAXOSMITHKLINE,,,,N,F,Y,,,20150220,N,OT,NG,NG,Efavirenz,Cleft palate;Foetal exposure during pregnancy;Hearing impaired;Live birth,108465611,OT,,,,,,,,,108465611,1,HIV infection
10847065,108470651,1,I,2012,20150116,20150220,20150220,EXP,,US-GLAXOSMITHKLINE-US2015005970,GLAXOSMITHKLINE,,,,,M,Y,,,20150220,N,CN,COUNTRY NOT SPECIFIED,US,SUSTIVA,Visual acuity reduced,,,,,108470651,1,2011,,,,108470651,1,HIV infection
10849060,108490601,1,I,,20150216,20150221,20150221,EXP,,IN-AUROBINDO-AUR-APL-2015-01366,AUROBINDO,,14,YR,,M,Y,,,20150221,N,OT,US,IN,Efavirenz,Gastrointestinal disorder;Neuropathy peripheral;Seizure;Toxicity to various agents;Tuberculoma of central nervous system,108490601,OT,,,108490601,1,20070727,,,,108490601,1,Pulmonary tuberculosis
10849539,108495391,1,I,,20140425,20150221,20150221,PER,,US-CELGENEUS-163-21880-14045858,CELGENE,,,,,M,Y,81.6,KG,20150221,N,OT,US,US,SUSTIVA,Adverse drug reaction,108495391,OT,,,108495391,1,200811,,,,108495391,1,Plasma cell myeloma
10852881,108528812,2,F,,20150216,20150223,20150223,EXP,,IN-AUROBINDO-AUR-APL-2015-01369,AUROBINDO,,16,YR,,F,Y,,,20150223,N,OT,US,IN,Efavirenz,Gastrointestinal disorder;Psychotic disorder;Tuberculoma of central nervous system,108528812,OT,,,108528812,1,20110215,,,,108528812,1,Pulmonary tuberculosis
10853519,108535191,1,I,,20150209,20150223,20150223,EXP,,IN-RANBAXY-2015R1-93256,RANBAXY,"ISAAKIDIS P, PARYANI R, KHAN S, MANSOOR H, MANGLANI M, VALIYAKATH A ET AL. POOR OUTCOMES IN A COHORT OF HIV-INFECTED ADOLESCENTS UNDERGOING TREATMENT FOR MULTIDRUG-RESISTANT TUBERCULOSIS IN MUMBAI, INDIA. PLOS ONE. 2013;JUL;8(7):E68869",14,YR,,M,Y,,,20150223,N,OT,IN,IN,Efavirenz,Abdominal discomfort;Neuropathy peripheral;Seizure;Tuberculoma of central nervous system,108535191,OT,,,108535191,4,20070727,,,,108535191,1,Antiretroviral therapy
10853561,108535611,1,I,,20150209,20150223,20150223,EXP,,IN-RANBAXY-2015R1-93273,RANBAXY,"ISAAKIDIS P, PARYANI R, KHAN S, MANSOOR H, MANGLANI M, VALIYAKATH A ET AL. POOR OUTCOMES IN A COHORT OF HIV-INFECTED ADOLESCENTS UNDERGOING TREATMENT FOR MULTIDRUG-RESISTANT TUBERCULOSIS IN MUMBAI, INDIA. PLOS ONE. 2013;JUL;8(7):E68869",16,YR,,F,Y,,,20150223,N,OT,IN,IN,Efavirenz,Gastrointestinal infection;Mental disorder;Tuberculoma of central nervous system,108535611,OT,,,108535611,4,20110215,,,,108535611,1,Antiretroviral therapy
10854150,108541501,1,I,,20150216,20150223,20150223,EXP,,IN-AUROBINDO-AUR-APL-2015-01373,AUROBINDO,,18,YR,,M,Y,,,20150223,N,OT,US,IN,Efavirenz,Gastrointestinal disorder;Hypokalaemia;Hypothyroidism;Neuropathy peripheral;Toxicity to various agents,108541501,HO,,,108541501,1,20121023,,,,108541501,1,Pulmonary tuberculosis
10854364,108543641,1,I,,20150216,20150223,20150223,EXP,,IN-AUROBINDO-AUR-APL-2015-01368,AUROBINDO,,18,YR,,F,Y,,,20150223,N,OT,US,IN,Efavirenz,Death;Neuropathy peripheral;Toxicity to various agents,108543641,DE,,,108543641,4,20080619,,,,108543641,1,HIV infection
10855811,108558113,3,F,20150208,20150224,20150223,20150309,EXP,,UG-009507513-1502UGA007918,MERCK,,30,YR,,F,Y,,,20150309,N,CN,UG,UG,EFAVIRENZ,Aspartate aminotransferase increased;Hepatotoxicity,108558113,HO,,,108558113,1,20141216,20150211,,,108558113,1,HIV infection
10857041,108570411,1,I,,20150212,20150223,20150223,EXP,,US-BMSGILMSD-2015-0137726,GILEAD,,63,YR,A,M,Y,,,20150223,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,108570411,OT,,,108570411,1,2004,,,,108570411,1,HIV infection
10858191,108581912,2,F,,20150310,20150223,20150318,EXP,,MX-GILEAD-2015-0138249,GILEAD,"SIERRA-MADERA JG, ELLENBERG SS, RASSOOL MS, ET AL. EFFECT OF THE CCRS ANTAGONIST MARAVIROC ON THE OCCURRENCE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV (CADIRIS): A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL.. THE LANCET HIV. 2014;1:PP E60-E67",,,A,,Y,,,20150318,N,OT,MX,MX,EFAVIRENZ,Hepatitis toxic,108581912,OT,,,,,,,,,108581912,1,HIV infection
10860716,108607161,1,I,20111203,20141215,20150224,20150224,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-003682,BRISTOL MYERS SQUIBB,,0,DY,,,Y,.31,KG,20150224,N,CN,US,AR,EFAVIRENZ,Foetal exposure during pregnancy;Live birth;Plagiocephaly,108607161,OT,,,,,,,,,108607161,1,HIV infection
10861281,108612812,2,F,20141203,20141218,20150224,20150226,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-002624,BRISTOL MYERS SQUIBB,,9,YR,,F,Y,22.65,KG,20150226,N,CN,US,US,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Diarrhoea;Drug eruption;Vomiting,108612812,HO,,,108612812,1,20141118,20141204,,,108612812,1,Antiretroviral therapy
10862522,108625221,1,I,,20150210,20150219,20150219,EXP,,US2015GSK018734,VIIV,,14,YR,,M,N,,,20150217,N,OT,US,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Abdominal pain;Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Kidney enlargement;Lymphadenopathy;Nephropathy toxic;Neuropathy peripheral;Pyrexia;Tubulointerstitial nephritis;Vomiting,108625221,HO,108625221,LIT,,,,,,,108625221,1,Acquired immunodeficiency syndrome
10863737,108637371,1,I,,20150216,20150224,20150224,EXP,,US-GILEAD-2015-0138038,GILEAD,,,,,M,Y,,,20150224,N,MD,US,US,SUSTIVA,Fat redistribution;Fat tissue increased;Lipoatrophy,,,,,,,,,,,108637371,1,Product used for unknown indication
10866160,108661601,1,I,,20150209,20150220,20150220,EXP,,MX2015GSK022049,VIIV,,,,,,N,,,20150218,N,MD,MX,,EFAVIRENZ,Hepatitis toxic,108661601,OT,108661601,HP,,,,,,,108661601,1,HIV infection
10866843,108668436,6,F,20150114,20150310,20150225,20150320,EXP,,MW-009507513-1502MWI010173,MERCK,,39,YR,,M,Y,,,20150320,N,OT,GB,MW,EFAVIRENZ,Meningitis;Sepsis,108668436,HO,,,108668436,1,20141219,,,,108668436,1,HIV infection
10868291,108682912,2,F,20150205,20150211,20150225,20150327,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010488,BRISTOL MYERS SQUIBB,,30,YR,,M,Y,,,20150327,N,CN,GB,ZW,EFAVIRENZ,Deep vein thrombosis,108682912,HO,,,108682912,1,20150108,,,,108682912,1,Antiretroviral therapy
10870030,108700302,2,F,,20150303,20150226,20150313,EXP,,NL-AUROBINDO-AUR-APL-2015-01591,AUROBINDO,,23,YR,,F,Y,,,20150313,N,OT,NL,NL,Efavirenz,Treatment failure,108700302,OT,,,,,,,,,108700302,1,HIV infection
10872255,108722551,1,I,2006,20150115,20150226,20150226,EXP,,US-GILEAD-2015-0132535,GILEAD,,42,YR,A,M,Y,70.3,KG,20150226,N,CN,US,US,SUSTIVA,Abnormal dreams;Depressed level of consciousness;Feeling abnormal;Nausea;Renal disorder;Renal impairment;Somnolence,108722551,OT,,,108722551,1,2006,2007,,,108722551,1,HIV infection
10872380,108723804,4,F,20150114,20150304,20150226,20150319,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010566,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20150319,N,CN,GB,MW,EFAVIRENZ,Meningitis;Sepsis,108723804,HO,,,108723804,1,20141219,,,,108723804,1,HIV infection
10873013,108730131,1,I,,20150208,20150223,20150223,EXP,,NG2015GSK023192,VIIV,,,,,F,N,,,20150220,N,OT,NG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cleft palate;Hearing impaired;Maternal drugs affecting foetus,108730131,OT,108730131,SDY,,,,,,,108730131,1,HIV infection
10873119,108731191,1,I,,20150208,20150223,20150223,EXP,,NG2015GSK023178,VIIV,,,,,F,N,,,20150220,N,OT,NG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Cleft palate;Live birth;Maternal drugs affecting foetus,108731191,OT,108731191,SDY,,,,,,,108731191,1,HIV infection
10873283,108732832,2,F,20111222,20150212,20150227,20150227,EXP,,GB-JNJFOC-20150210066,JANSSEN,,57,YR,A,M,Y,90.8,KG,20150227,N,OT,GB,GB,EFAVIRENZ,Chest pain,108732832,OT,,,108732832,1,20111216,20120106,,,108732832,1,HIV infection
10873994,108739941,1,I,20141203,20141208,20150227,20150227,EXP,,ZA-009507513-1412ZAF004514,MERCK,,9,YR,,F,Y,22.65,KG,20150227,N,CN,US,ZA,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Diarrhoea;Drug eruption;Vomiting,108739941,HO,,,108739941,1,20141118,20141124,,,108739941,1,Antiretroviral therapy
10875397,108753972,2,F,20141119,20150317,20150227,20150324,EXP,,ZA-GILEAD-2015-0139347,GILEAD,,38,YR,A,F,Y,,,20150324,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,108753972,OT,,,108753972,1,20140625,,,,108753972,1,HIV infection
10880691,108806911,1,I,,20150210,20150226,20150226,EXP,,2015HINLIT0175,HETERO,,16,YR,,F,N,,,20150224,N,OT,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Gastrointestinal disorder;Psychotic disorder;Toxicity to various agents;Tuberculoma of central nervous system,108806911,OT,108806911,HP,108806911,4,20111215,,,,108806911,1,Antiretroviral therapy
10880695,108806951,1,I,,20150210,20150226,20150226,EXP,,2015HINLIT0172,HETERO,,14,YR,,M,N,,,20150224,N,OT,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Gastrointestinal disorder;Neuropathy peripheral;Seizure;Tuberculoma of central nervous system,108806951,DE,108806951,FGN,108806951,5,20070727,,,,108806951,1,Antiretroviral therapy
10881845,108818452,2,F,20140710,20150312,20150303,20150319,EXP,,MW-GILEAD-2015-0139377,GILEAD,,38,YR,A,M,Y,,,20150319,N,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis cryptococcal,108818452,HO,,,108818452,1,20140304,,,,108818452,1,HIV infection
10888950,108889501,1,I,201410,20150226,20150305,20150305,EXP,,US-BMSGILMSD-2015-0140194,GILEAD,,41,YR,A,M,Y,,,20150305,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Heart valve operation,108889501,OT,,,,,,,,,108889501,1,HIV infection
10891605,108916051,1,I,,20150302,20150306,20150306,EXP,,IN-GLAXOSMITHKLINE-IN2015GSK029621,GLAXOSMITHKLINE,,14,YR,,M,Y,,,20150306,N,MD,IN,IN,Efavirenz,Abnormal behaviour;Clumsiness;Disturbance in attention;Dyskinesia;Fall;Myoclonus;Subacute sclerosing panencephalitis,108916051,OT,,,,,,,,,108916051,1,HIV infection
10893944,108939441,1,I,,20150224,20150306,20150306,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-012500,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150306,N,MD,US,US,SUSTIVA,Wrong technique in drug usage process,,,,,,,,,,,108939441,1,Product used for unknown indication
10894999,108949993,3,F,201501,20150318,20150306,20150323,EXP,,UG-GILEAD-2015-0140055,GILEAD,,38,YR,A,F,Y,68.7,KG,20150323,N,MD,UG,UG,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Uterine haemorrhage,108949993,OT,,,108949993,1,20131021,20131002,,,108949993,1,HIV infection
10896658,108966582,2,F,,20150310,20150302,20150320,EXP,,MX2015024076,VIIV,,,,,,N,,,20150318,N,OT,MX,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Hepatitis toxic,108966582,OT,108966582,FGN,,,,,,,108966582,1,HIV infection
10901710,109017102,2,F,20150112,20150310,20150310,20150325,EXP,,UG-009507513-1502UGA010752,MERCK,,32,YR,,F,Y,39,KG,20150325,N,CN,US,UG,EFAVIRENZ,Sudden death,109017102,DE,,,109017102,1,20150107,20150111,,,109017102,1,HIV infection
10902078,109020781,1,I,,20150302,20150310,20150310,EXP,,US-JNJFOC-20150302916,JANSSEN,,53,YR,A,F,Y,,,20150310,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,109020781,OT,,,109020781,2,20131028,20140410,,,109020781,1,HIV infection
10902455,109024551,1,I,20150204,20150212,20150310,20150310,EXP,,UG-009507513-1502UGA012137,MERCK,,30,YR,,F,Y,,,20150310,N,CN,US,UG,EFAVIRENZ,Coma;Death,109024551,DE,,,109024551,1,20140909,20141105,,,109024551,1,HIV infection
10902831,109028311,1,I,,20150302,20150310,20150310,EXP,,US-BMSGILMSD-2015-0140813,GILEAD,,71,YR,E,M,Y,,,20150310,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,109028311,OT,,,,,,,,,109028311,1,HIV infection
10902832,109028321,1,I,,20150303,20150310,20150310,EXP,,US-BMSGILMSD-2015-0140801,GILEAD,,66,YR,E,M,Y,,,20150310,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,109028321,OT,,,,,,,,,109028321,1,HIV infection
10905707,109057071,1,I,20140508,20150303,20150311,20150311,EXP,,IT-GILEAD-2015-0141152,GILEAD,"D?AVINO A, LASSANDRO A, LAMONICA S, PICCOLI B, FABBIANI M, MONDI A, GAGLIARDINI R, BORGHETTI A, FANTI L, PALLAVICINI F, CAUDA R, DI GIAMBENEDETTO S. PREVALENCE OF OSTEOPOROSIS AND PREDICTORS OF LOW BMD IN A COHORT OF HIV-1 INFECTED PATIENTS IN ROME: A POPULATION AT HIGH RISK. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2014;UNK:UNK",46,YR,A,M,Y,72,KG,20150311,N,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,109057071,OT,,,109057071,1,20090428,20140408,,,109057071,1,HIV infection
10908647,109086471,1,I,20140425,20140523,20150312,20150312,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-20861415,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,62.5,KG,20150312,N,OT,US,BR,EFAVIRENZ,Depression suicidal,109086471,OT,,,109086471,1,20131202,20140424,,,109086471,1,HIV infection
10911991,109119911,1,I,,20150302,20150309,20150309,EXP,,IN2015GSK029621,VIIV,,14,YR,,M,N,,,20150306,N,MD,IN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Abnormal behaviour;Clumsiness;Disturbance in attention;Dyskinesia;Fall;Myoclonus;Subacute sclerosing panencephalitis,109119911,OT,109119911,LIT,,,,,,,109119911,1,HIV infection
10913576,109135761,1,I,201410,20150218,20150313,20150313,EXP,,FR-GILEAD-2015-0138625,GILEAD,,72,YR,E,M,Y,47,KG,20150313,N,MD,FR,FR,SUSTIVA,Drug resistance;Renal impairment;Tubulointerstitial nephritis,109135761,OT,,,109135761,1,201405,201502,,,109135761,1,Hepatitis B
10920208,109202081,1,I,,20150306,20150317,20150317,EXP,,ES-CIPLA LTD.-2015ES01987,CIPLA,"PODZAMCZER.D, TIRABOSCHI.JM, MORENO.JA, PUERTAS.MC, VILLAVERDE.C, PRATS.A, FERRER.E, ROZAS.N, MASO.M, OUCHI.D, PICADO.J.. VIRAL AND INFLAMMATORY MARKERS IN CEREBROSPINAL FLUID OF PATIENTS WITH HIV-1-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING ANTIRETROVIRAL TREATMENT SWITCH. HIV MEDICINE. 2015;1-5",,,,,Y,,,20150317,N,OT,ES,ES,Efavirenz,Viral load increased,109202081,OT,,,,,,,,,109202081,1,HIV infection
10921481,109214811,1,I,,20150306,20150317,20150317,EXP,,ES-CIPLA LTD.-2015ES01985,CIPLA,"PODZAMCZER.D, TIRABOSCHI.JM, MORENO.JA, PUERTAS.MC, VILLAVERDE.C, PRATS.A, FERRER.E, ROZAS.N, MASO.M, OUCHI.D, PICADO.J.. VIRAL AND INFLAMMATORY MARKERS IN CEREBROSPINAL FLUID OF PATIENTS WITH HIV-1-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING ANTIRETROVIRAL TREATMENT SWITCH. HIV MEDICINE. 2015;1-5",,,,,Y,,,20150317,N,OT,ES,ES,Efavirenz,Treatment failure,109214811,OT,,,,,,,,,109214811,1,HIV infection
10921665,109216651,1,I,,20150303,20150317,20150317,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-014396,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150317,N,CN,GB,GB,SUSTIVA,Hand fracture,109216651,OT,,,,,,,,,109216651,1,Product used for unknown indication
10922715,109227151,1,I,,20150311,20150317,20150317,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK033533,GLAXOSMITHKLINE,,,,,F,Y,,,20150317,N,CN,GB,GB,SUSTIVA,Malaise;Surgery,109227151,HO,,,,,,,,,109227151,1,Product used for unknown indication
10923869,109238691,1,I,201403,20140414,20150129,20150129,PER,,K201490302,VIIV,,73,YR,,M,N,,,20150125,N,CN,US,,SUSTIVA,Abdominal pain upper,109238691,HO,109238691,CSM,109238691,1,2011,,,,109238691,1,HIV infection
10925981,109259811,1,I,,20150311,20150318,20150318,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK032660,GLAXOSMITHKLINE,,,,,M,Y,,,20150318,N,CN,GB,GB,SUSTIVA,Lower respiratory tract infection,109259811,OT,,,,,,,,,109259811,1,Product used for unknown indication
10930823,109308231,1,I,,20150305,20150319,20150319,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-014932,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150319,N,CN,GB,GB,SUSTIVA,Lower respiratory tract infection;Off label use,109308231,OT,,,,,,,,,109308231,1,Short-bowel syndrome
10931547,109315471,1,I,20131006,20131028,20150319,20150319,EXP,,KE-ASTELLAS-2015US007105,ASTELLAS,,48,YR,,M,Y,,,20150306,N,CN,GB,KE,EFAVIRENZ,Acute kidney injury;Anaemia;Meningitis cryptococcal,109315471,OT,,,109315471,1,20131011,20131023,,,109315471,1,Product used for unknown indication
10932862,109328621,1,I,,20150312,20150320,20150320,EXP,,US-BMSGILMSD-2015-0142466,GILEAD,,41,YR,A,M,Y,,,20150320,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Overdose,109328621,HO,,,109328621,1,20150220,20150304,,,109328621,1,HIV infection
10932955,109329552,2,F,20141210,20150316,20150320,20150323,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-015418,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20150323,N,CN,ZW,ZW,EFAVIRENZ,Anaemia;HIV infection;Weight decreased,109329552,DE,,,109329552,1,20140108,20141209,,,109329552,1,HIV infection
10936068,109360681,1,I,,20150313,20150320,20150320,EXP,,US-BMSGILMSD-2015-0142903,GILEAD,,43,YR,A,M,Y,,,20150320,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,109360681,OT,,,,,,,,,109360681,1,HIV infection
10945449,109454491,1,I,,20150311,20150319,20150319,EXP,,GB2015GSK033533,VIIV,,,,,F,N,,,20150317,N,CN,GB,,SUSTIVA,Malaise;Surgery,109454491,HO,109454491,CSM,,,,,,,109454491,1,Product used for unknown indication
10945477,109454771,1,I,,20150311,20150319,20150319,EXP,,GB2015GSK032660,VIIV,,62,YR,,M,N,,,20150317,N,CN,GB,,SUSTIVA,Lower respiratory tract infection,109454771,OT,109454771,CSM,,,,,,,109454771,1,Product used for unknown indication
10949689,109496891,1,I,,20150316,20150324,20150324,EXP,,US-GILEAD-2015-0143471,GILEAD,,66,YR,E,M,Y,,,20150324,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes abnormal;Diabetes mellitus;Drug ineffective;Drug resistance;Hyperlipidaemia;Hypertension,109496891,OT,,,109496891,1,201111,,,,109496891,1,Product used for unknown indication
10950692,109506921,1,I,20110120,20150311,20150324,20150324,EXP,,IN-MYLANLABS-2015M1009374,MYLAN,"KRISHNARAJ R, CHOCKALINGAM C, KRISHNARAJASEKHAR OR, AYYAMPERUMAL M, NARAYANAN R, SATAGOPAN K. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) WITH ACUTE TUBERCULOUS OSTEOMYELITIS AND DISSEMINATED MUTILATING TUBERCULOUS DACTYLITIS IN A PERSON LIVING WITH HIV AND AIDS (PLHA): A CASE REPORT. J-INT-ASSOC-PHYS-AIDS-CARE 2012; 11(5):289-92.",,,,,Y,,,20150324,N,MD,IN,IN,EFAVIRENZ,Dactylitis;Immune reconstitution inflammatory syndrome associated tuberculosis;Osteomyelitis acute,109506921,OT,,,109506921,1,20101222,,,,109506921,1,HIV infection
10950906,109509061,1,I,20140610,20140613,20150324,20150324,EXP,,ZW-GILEAD-2014-0105557,GILEAD,,36,YR,A,F,Y,43,KG,20150324,N,MD,ZW,ZW,EFAVIRENZ,Renal failure,109509061,DE,,,109509061,1,20140127,20140609,,,109509061,1,HIV infection
10954982,109549821,1,I,,20150316,20150325,20150325,EXP,,US-BMSGILMSD-2015-0143446,GILEAD,,41,YR,A,M,Y,,,20150325,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Hypertension,109549821,OT,,,109549821,1,200803,,,,109549821,1,Product used for unknown indication
10955026,109550261,1,I,,20150312,20150325,20150325,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-016752,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150325,N,CN,GB,GB,SUSTIVA,Malaise;Surgery,109550261,HO,,,,,,,,,109550261,1,Product used for unknown indication
10957658,109576581,1,I,,20150316,20150326,20150326,EXP,,US-BMSGILMSD-2015-0143504,GILEAD,,47,YR,A,M,Y,,,20150326,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Hypertension,109576581,OT,,,109576581,1,201011,,,,109576581,1,Product used for unknown indication
10957662,109576621,1,I,,20150316,20150326,20150326,EXP,,US-GILEAD-2015-0143505,GILEAD,,74,YR,E,M,Y,,,20150326,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Hyperlipidaemia;Hypertension,109576621,OT,,,109576621,1,201410,,,,109576621,1,Product used for unknown indication
10957689,109576891,1,I,,20150316,20150326,20150326,EXP,,US-BMSGILMSD-2015-0144027,GILEAD,,71,YR,E,F,Y,,,20150326,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiovascular disorder;Depression;Diabetes mellitus;Renal failure,109576891,OT,,,109576891,1,201403,,,,109576891,1,Product used for unknown indication
10958458,109584581,1,I,,20150318,20150326,20150326,EXP,,UG-GILEAD-2015-0143659,GILEAD,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G, OLSSON S AND PAL S. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA.. DRUG SAFETY.. 2015;UNK:UNK",38,YR,A,M,Y,,,20150326,N,OT,UG,UG,EFAVIRENZ,Death,109584581,OT,,,,,,,,,109584581,1,HIV infection
10960185,109601851,1,I,20000301,,20150326,20150326,DIR,,,,,43,YR,,M,N,,,20150324,N,,US,,SUSTIVA,Abnormal dreams,,,,,109601851,1,1997,,,,,,
10961895,109618951,1,I,20141115,20150313,20150327,20150327,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-017609,BRISTOL MYERS SQUIBB,,59,YR,,F,Y,56,KG,20150327,N,CN,US,BR,EFAVIRENZ,Acute pulmonary oedema;American trypanosomiasis;Cardiac failure congestive;Cardiomyopathy,109618951,DE,,,109618951,1,20141020,,,,109618951,1,HIV infection
10961951,109619511,1,I,201211,20150312,20150327,20150327,EXP,,JP-GILEAD-2015-0143616,GILEAD,,37,YR,A,M,Y,,,20150327,N,MD,JP,JP,EFAVIRENZ,Abulia;Brain death;Central nervous system lymphoma;Decreased appetite;Disorientation;Dysarthria;Dyspnoea;Fatigue;Hyperreflexia;JC virus infection;Lethargy;Locked-in syndrome;Progressive multifocal leukoencephalopathy;Pyrexia,109619511,DE,,,,,,,,,109619511,1,HIV infection
10962476,109624761,1,I,,20150323,20150327,20150327,EXP,GB-MHRA-ADR 22919276,GB-GLAXOSMITHKLINE-GB2015038006,GLAXOSMITHKLINE,,62,YR,,M,Y,,,20150327,N,CN,GB,GB,SUSTIVA,Lower respiratory tract infection;Off label use,109624761,OT,,,,,,,,,109624761,1,Product used for unknown indication
10968228,109682281,1,I,,20150324,20150330,20150330,EXP,,BR-ABBVIE-15P-020-1366225-00,ABBVIE,,,,,,Y,,,20150330,N,OT,COUNTRY NOT SPECIFIED,BR,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby,109682281,OT,,,,,,,,,109682281,1,Maternal exposure timing unspecified
10968837,109688371,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02466,CIPLA,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G ET.AL.. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAFS. 2015",,,,,Y,,,20150330,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Lipodystrophy acquired,109688371,OT,,,109688371,2,2006,,,,109688371,1,HIV test positive
10968852,109688521,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02482,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015;1-14",,,,,Y,,,20150330,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109688521,OT,,,,,,,,,109688521,1,HIV infection
10968912,109689121,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02479,CIPLA,"NDAGIJE H, NAMBASA V, NAMAGALA E, NASSALI H, KAJUNGU D, SEMATIKO G ET.AL.. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAFS. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Neutropenia;Protein urine present,109689121,OT,,,,,,,,,109689121,1,HIV infection
10968950,109689501,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02486,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood urine present;Protein urine;Urinary tract infection;White blood cells urine positive,109689501,OT,,,,,,,,,109689501,1,HIV test positive
10968953,109689531,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02497,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109689531,OT,,,,,,,,,109689531,1,HIV test positive
10968961,109689611,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02498,CIPLA,"NDAGIJE.H, NAMBASA.V, NAMAGALA.E, NASSALI.H, KAJUNGU.D, SEMATIKO.G, OLSSON.S, PAL.S.. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015;1-14",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Anaemia;Death;Hydronephrosis;Oedema peripheral;Protein urine,109689611,DE,,,,,,,,,109689611,1,HIV infection
10969104,109691041,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02502,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased,109691041,LT,,,,,,,,,109691041,1,HIV infection
10969109,109691091,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02506,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Protein urine present;Renal tubular necrosis,109691091,OT,,,,,,,,,109691091,1,HIV test positive
10969110,109691101,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02499,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON, SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Kaposi's sarcoma,109691101,OT,,,,,,,,,109691101,1,HIV test positive
10969131,109691311,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02509,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Bone density decreased;Bone formation decreased,109691311,OT,,,,,,,,,109691311,1,HIV test positive
10969133,109691331,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02510,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Haematuria,109691331,OT,,,,,,,,,109691331,1,HIV test positive
10969135,109691351,1,I,,20150316,20150331,20150331,EXP,,UG-CIPLA LTD.-2015UG02511,CIPLA,"HELEN NDAGIJE, VICTORIA NAMBASA,  ELIZABETH NAMAGALA, HULDAH NASSALI, DAN KAJUNGU, GORDON SEMATIKO, STEN OLSSON AND SHANTHI PAL. TARGETED SPONTANEOUS REPORTING OF SUSPECTED RENAL TOXICITY IN PATIENTS UNDERGOING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN TWO PUBLIC HEALTH FACILITIES IN UGANDA. DRUG SAF. 2015",,,,,Y,,,20150331,N,OT,UG,UG,Efavirenz,Blood creatinine increased;Protein urine present,109691351,OT,,,,,,,,,109691351,1,HIV test positive
10971671,109716711,1,I,200011,20150325,20150331,20150331,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-16629GD",BOEHRINGER INGELHEIM,"RAZONABLE R,AKSAMIT A,WRIGHT A,WILSON J. CIDOFOVIR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. MAYO CLIN PROC 2001 NOV;76:11:1171-1175.",55,YR,,M,Y,,,20150331,N,OT,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Immune system disorder;Progressive multifocal leukoencephalopathy,109716711,OT,,,109716711,1,200009,200009,,,109716711,1,Acquired immunodeficiency syndrome
10972647,109726471,1,I,,20150318,20150331,20150331,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-017763,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150331,N,MD,US,US,SUSTIVA,Erythema multiforme,109726471,OT,,,,,,,,,109726471,1,Product used for unknown indication
10978739,109787391,1,I,201503,20150324,20150331,20150331,EXP,,RU2015GSK039343,VIIV,,37,YR,,M,N,75.0,KG,20150329,N,MD,RU,,STOCRIN (EFAVIRENZ) (EFAVIRENZ) TABLET,Acute myocardial infarction,109787391,OT,109787391,FGN,109787391,1,20120411,,,,109787391,1,HIV infection
10978750,109787501,1,I,,20150323,20150331,20150331,EXP,,GB2015038006,VIIV,,62,YR,,M,N,,,20150327,N,CN,GB,,SUSTIVA,Lower respiratory tract infection;Off label use,109787501,OT,109787501,FGN,,,,,,,109787501,1,Product used for unknown indication
9204808,92048083,3,F,20130318,20150317,20130402,20150330,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-18723148,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,52.5,KG,20150330,N,CN,US,MW,EFAVIRENZ,Meningitis tuberculous,92048083,LT,,,92048083,1,20130116,20130718,,,92048083,1,HIV infection
9361763,93617633,3,F,20090415,20150130,20130621,20150212,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-19029164,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20150212,N,CN,US,JP,EFAVIRENZ,Blood alkaline phosphatase increased;Femur fracture;Gynaecomastia;Hyperthyroidism;White blood cell count increased,93617633,HO,,,93617633,1,20010919,20120531,,,93617633,1,HIV infection
9438099,94380994,4,F,2007,20150217,20130802,20150303,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-18931295,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150303,N,OT,AT,AT,EFAVIRENZ,Neurotoxicity,94380994,OT,,,,,,,,,94380994,1,HIV infection
9495399,94953992,2,F,20130304,20150313,20130903,20150320,EXP,,MX-GILEAD-2013-0082261,GILEAD,,41,YR,A,M,Y,65.31,KG,20150320,N,MD,MX,MX,EFAVIRENZ,Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased,94953992,OT,,,94953992,1,20110803,20130303,,,94953992,1,HIV infection
9657874,96578743,3,F,20131006,20131028,20131030,20150303,EXP,,KE-GILEAD-2013-0086214,GILEAD,,48,YR,A,M,Y,,,20150303,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Anaemia;Meningitis cryptococcal,96578743,OT,,,96578743,1,20130924,20131009,,,96578743,1,HIV infection
9859943,98599434,4,F,20140512,20150127,20140131,20150203,EXP,,GB-GILEAD-2014-0093204,GILEAD,,40,YR,A,F,Y,,,20150203,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alpha 1 foetoprotein;Stillbirth,98599434,OT,,,,,,,,,98599434,1,HIV infection
9981432,99814322,2,F,20130709,20140224,20140307,20150114,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-20386363,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20150114,N,CN,US,BW,EFAVIRENZ,Foetal exposure during pregnancy;Stillbirth,99814322,DE,,,99814322,1,20130103,20130313,,,99814322,1,Product used for unknown indication
